Abstract
Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that causes severe neurological complications that include congenital abnormalities and Guillain-Barré syndrome. So far, no effective vaccine or therapy against ZIKV is available. Development of therapeutic antibodies and drugs is an urgent area of research. For flavivirus infections, neutralizing antibodies are the essential components of protective immunity in humans. Recently, much effort has been spent on screening for antibodies that target different epitopes. Verification of the epitope information is important not only for the development of antibody-based therapy but also for the structure-based vaccine design against ZIKV infection in humans. In this chapter, we review the development of human antibodies according to their targeting epitopes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
